Table 2.
Univariate and multivariate Cox regression analysis for the association of patient and treatment factors with grade ≥ 2 acute GI toxicity
| Univariate | Multivariate | |||
|---|---|---|---|---|
| Variables | p | OR(CI) | p | OR(CI) |
| SV invasion risk group | ||||
| 1 vs 2 | 0.53 | 1.9(0.25-14.4) | - | - |
| 1 vs 3 | 0.38 | 2.5(0.32-19.6) | - | - |
| Age (<70 vs ≥ 70) | 0.76 | 0.89(0.42-1.9) | - | - |
| ADT (yes vs no) | 0.54 | 0.13(0.56-0.29) | - | - |
| T stage | ||||
| T1 vs T2 | 0.3 | 0.28(0.38-21.5) | - | - |
| T1 vs T3 | 0.7 | 1.4(0.19-11.6) | - | - |
| Risk group | ||||
| Low vs intermediate | 0.1 | 2.3(0.83-6.3) | - | - |
| Low vs high | 0.26 | 1.8(0.65-4.8) | - | - |
| PSA | ||||
| <10 vs 10-20 | 0.69 | 1.3(0.38-4.5) | - | - |
| <10 vs >20 | 0.23 | 2.2(0.6-8.2) | - | - |
| Gleason score | ||||
| 6 vs 7 | 0.23 | 2.5(0.6-10.9) | - | - |
| 6 vs 8-9 | 0.56 | 1.6(0.35-7.1) | - | - |
| Positive biopsy cores (<50% vs ≥ 50%) | 0.46 | 1.35(0.6-3.07) | - | - |
SV: seminal vesicles, ADT: androgen deprivation therapy, PSA: prostate specific antigen